Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Ingredient Mepolizumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Rotigotine

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the Active Ingredient Infliximab

Open House Biologics Rebate Agreements 2023-03 - Interferon Beta-1A (Prepared Drug Name: Avonex(R))

Conclusion of Non-Exclusive Discount Agreements According to Section 130A Paragraph 8 Sgb V for the Active Ingredient Certolizumab Pegol

5 Types of Maintenance Logistics

1 Type of Hospital or Preserved Juice

Afwerx Challenge Commercial Solutions Opening (Cso)

Ypo - 001086 Apprenticeships